MapLight Therapeutics (MPLT) analyst forecast and price target
Analyst forecast
Consensus of 14 analyst ratings
Based on 9 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Needham | Maintained | Buy | $43.00 from $45.00 | Aug 31, 2026 |
| UBS | Downgraded | Buy → Neutral | $13.00 from $52.00 | Aug 10, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $26.00 from $45.00 | Jul 28, 2026 |
| Morgan Stanley | Downgraded | Overweight → Equal-Weight | $21.00 from $34.00 | Jul 28, 2026 |
| Canaccord Genuity | Maintained | Buy | $24.00 from $43.00 | Jul 28, 2026 |
| Canaccord Genuity | Maintained | Buy | $43.00 from $35.00 | Jul 24, 2026 |
| BMO Capital | Initiated Coverage | Outperform | $46.00 | Jul 21, 2026 |
| UBS | Maintained | Buy | $52.00 from $48.00 | Jul 21, 2026 |
| Needham | Maintained | Buy | $45.00 from $42.00 | Jul 10, 2026 |
| Raymond James | Initiated Coverage | Strong Buy | $46.00 | Jun 25, 2026 |
| Craig-Hallum | Maintained | Buy | $40.00 from $43.00 | Jun 23, 2026 |
| Needham | Maintained | Buy | $42.00 from $37.00 | Jun 22, 2026 |
| Stifel | Maintained | Buy | $36.00 from $28.00 | Jun 2, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $45.00 | May 28, 2026 |
| UBS | Initiated Coverage | Buy | $48.00 | May 27, 2026 |
| Craig-Hallum | Initiated Coverage | Buy | $43.00 | May 21, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $45.00 | May 4, 2026 |
| Needham | Initiated Coverage | Buy | $37.00 | Apr 8, 2026 |
| TD Cowen | Initiated Coverage | Buy | — | Apr 7, 2026 |
| Canaccord Genuity | Initiated Coverage | Buy | $35.00 | Mar 19, 2026 |
Frequently asked questions
What is the price target for MPLT stock?
The average 12-month analyst price target for MapLight Therapeutics (MPLT) is $32.78, with a high estimate of $46.00 and a low of $13.00, across 9 analysts.
Is MPLT a buy, sell, or hold?
Analysts covering MapLight Therapeutics currently average a Buy rating: 12 buy, 2 hold and 0 sell, from 14 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for MPLT?
The average price target of $32.78 implies 160.66% upside from the last price of $12.58.
What is the latest analyst rating on MPLT?
On Aug 31, 2026, Needham maintained MapLight Therapeutics at Buy with a price target of $43.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.